AstraZeneca Licenses Nicotinic Alzheimer’s Treatment From Targacept
Firm aims to bring the tobacco spin-off’s developmental neuronal nicotinic receptor modulator TC-1734 to market for Alzheimer’s and other cognitive disorders.
Firm aims to bring the tobacco spin-off’s developmental neuronal nicotinic receptor modulator TC-1734 to market for Alzheimer’s and other cognitive disorders.